Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7304302 | 0.91 | KMT2A (0.47) | MEN1KMT2AUSP2ALDH1A1L3MBTL1 | |
| SCHEMBL7303095 | 0.89 | KMT2A (0.46) | MEN1KMT2AUSP2ALDH1A1L3MBTL1 | |
| SCHEMBL27510315 | 0.87 | MEN1 (0.47) | MEN1KMT2AUSP2ALDH1A1L3MBTL1 | |
| SCHEMBL7308253 | 0.87 | ACP3 (0.47) | MEN1KMT2AUSP2ALDH1A1POLB | |
| SCHEMBL7308021 | 0.83 | LMNA (0.48) | MEN1KMT2AALDH1A1L3MBTL1POLB | |
| SCHEMBL28441070 | 0.81 | POLB (0.59) | MEN1KMT2AUSP2ALDH1A1L3MBTL1 | |
| SCHEMBL4378891 | 0.78 | MEN1 (0.76) | MEN1KMT2AUSP2ALDH1A1L3MBTL1 | |
| Hydrogen Peroxide SCHEMBL8527170 | 0.77 | KMT2A (0.68) | MEN1KMT2AALDH1A1L3MBTL1POLB | |
| SCHEMBL28434990 | 0.76 | NPC1 (0.56) | MEN1KMT2AL3MBTL1GAAMAPT | |
| SCHEMBL28318108 | 0.75 | MEN1 (0.66) | MEN1KMT2AUSP2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0644197-B1 | Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors | VERTEX PHARMA (US) | 1998-09-09 | — | — | EP | claimed |
| EP-1660464-B1 | CASPASE INHIBITORS CONTAINING ISOXAZOLINE RING | LG LIFE SCIENCES LTD (KR) | 2015-02-25 | — | — | EP | disclosed |
| US-7557133-B2 | Caspase inhibitors containing isoxazoline ring | LG LIFE SCIENCES LTD. (KR) | 2009-07-07 | — | — | US | disclosed |
| EP-1660464-A4 | CASPASE INHIBITORS CONTAINING ISOXAZOLINE RING | LG LIFE SCIENCES LTD (KR) | 2008-11-26 | — | — | EP | disclosed |
| US-20060223848-A1 | Caspase inhibitors containing isoxazoline ring | LG CHEM, LTD. (KR) | 2006-10-05 | — | — | US | disclosed |
| EP-1660464-A1 | CASPASE INHIBITORS CONTAINING ISOXAZOLINE RING | LG Life Sciences Ltd. (KR) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021516-A1 | CASPASE INHIBITORS CONTAINING ISOXAZOLINE RING | LG LIFE SCIENCES LTD. (KR) | 2005-03-10 | — | — | WO | disclosed |
| US-20020128434-A1 | Alpha-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors | ZIMMERMAN MARY P (US) | 2002-09-12 | — | — | US | disclosed |
| US-6147188-A | IRREVERSIBLE CATHEPSIN OR CALPAIN INHIBITORS | PROTOTEK, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| US-5985863-A | PHARMACEUTICAL COMPOSITIONS FOR DECREASING THE PRODUCTION OF INTERFERON-GAMMA INDUCING FACTOR (IGIF), AND INTERFERON-GAMMA (IFN-GAMMA) COMPRISING COMPOUND WHICH INHIBITS INTERLEUKIN-1.BETA. CONVERTING ENZYME (ICE) | VERTEX PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0863883-A4 | — | — | 1998-09-16 | — | — | EP | disclosed |
| EP-0863883-A1 | ALPHA-(1,3-DICARBONYLENOL ETHER) METHYL KETONES AS CYSTEINE PROTEASE INHIBITORS | PROTOTEK, INC., (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1998024814-A2 | N-TERMINALLY MODIFIED POLYPEPTIDE ENZYME INHIBITORS, AND RELATED THERAPEUTIC METHODS AND PHARMACEUTICAL COMPOSITIONS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| US-5714484-A | α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors | PROTOTEK, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| WO-1996040647-A1 | α-(1,3-DICARBONYLENOL ETHER) METHYL KETONES AS CYSTEINE PROTEASE INHIBITORS | PROTOTEK, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128434-A1 | Alpha-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors | CPN1, CTRL, SERPINB1 | MEN1 2826/4885KMT2A 1897/4885USP2 264/4885 |
| US-20060223848-A1 | Caspase inhibitors containing isoxazoline ring | CASP1, CASP7, CASP2 | MEN1 4843/4885KMT2A 4075/4885USP2 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.